Fig. 7: Antibody longevity of each bioconjugate vaccine in K4V. | npj Vaccines

Fig. 7: Antibody longevity of each bioconjugate vaccine in K4V.

From: A multivalent capsule vaccine protects against Klebsiella pneumoniae bloodstream infections in healthy and immunocompromised mice

Fig. 7: Antibody longevity of each bioconjugate vaccine in K4V.

Mice were immunized with monovalent formulations of EPA, K1-EPA, K2-EPA, KL102-EPA, or KL107-EPA. Mice were immunized on days 0, 14, and 28 and were bled every month for 6 months. Six-month serums were tested in a serum bactericidal assay against strains A NTUH-K2044, B cKp120, C, ATCC 43816, D KR174, E BEI 669448, or F BEI 702325. After six months, the EPA and K1-EPA immunized cages were challenged intraperitoneally with a lethal dose (~2000 CFU) of NTUH-K2044 and monitored for survival (G). Each data point represents a single mouse. Statistical analyses (A−F) were performed via the Mann-Whitney U test or via (G) Log-rank Mantel-Cox test in comparison to EPA survival. *p < 0.05, **p < 0.01. Error bars represent standard deviation. Exact p values: A* p = 0.0159. B **p = 0.0079. C **p = 0.0079. D **p = 0.0079. E *p = 0.0317. F *p = 0.0159. G **p = 0.0031.

Back to article page